Table 1 Main characteristics of included studies
From: Economic impact of HIV/AIDS: a systematic review in five European countries
Country | Author | Publication year | Journal | Sample size | Focus (according papers’ authors) | Focus (according reviewers) | Costs approximation (according papers’ authors) | Costs approximation (according reviewers) |
|---|---|---|---|---|---|---|---|---|
Spain | Domingo JM et al. | 1998 | Oficial Journal Of The International AIDS Society | 249 | No information | Prevalence | No information | Bottom-up |
Spain | Velasco M et al. | 2000 | HIV Medicine | 155 | No information | Prevalence | No information | Bottom-up |
Spain | Mompó C et al. | 2000 | Gaceta Sanitaria | 109 | No information | Prevalence | No information | Bottom-up |
Spain | Llibre-Codina JM et al. | 2007 | Enfermedades Infecciosas y Microbiologia Clínica | 1.286 | Prevalence | Prevalence | No information | Bottom-up |
Spain | Velasco M et al. | 2007 | European Journal Of Internal Medicine | 101 | No information | Prevalence | No information | Bottom-up |
Spain | Santolaya Perrín et al. | 2008 | The Annals Of Pharmacotherapy | 144 | No information | Prevalence | No information | Bottom-up |
Spain | Lopez-Bastida et al. | 2009 | BIOMEDCENTRAL Health Services Research | 572 | Prevalence | Prevalence | Bottom-up | Bottom-up |
Germany | Stoll M et al. | 2002 | Journal of Medical Research | 168 (average 3 years) | No information | Prevalence | No information | Bottom-up |
France | Mouton Y et al. | 1997 | Oficial Journal Of The International AIDS Society | 7.749 | No information | Prevalence | No information | Bottom-up |
France | Rahmouni S et al. | 1998 | International Society For Pharmacoeconomics And Outcomes Research | 1.558 | No information | Prevalence | No information | Bottom-up |
France | Peyron F et al. | 1999 | The Journal Of Pharmacy Technology | 257 | No information | Prevalence | No information | Bottom-up |
France | Le Pen C et al. | 2001 | HIV Clinical Trials | 500 | No information | Prevalence | No information | Bottom-up |
France | Yazdapnpanah Y et al. | 2002 | Antirretroviral Therapy | 1.232 | No information | Prevalence | Micro-costing | Bottom-up |
Italy | Floridia M et al. | 2000 | HIV Clinical Trials | 166 | Incidence | Incidence | No information | Bottom-up |
Italy | Garattini L et al. | 2001 | AIDS Care | 483 | No information | Prevalence | Micro-costing | Bottom-up |
Italy | Sabbatini S, Cesari R. | 2002 | Clinical Drug Investigation | 650 | No information | Prevalence | No information | Bottom-up |
Italy | Torti C et al. | 2003 | Health Policy | 1.268 (average 4 years) | No information | Prevalence | No information | Bottom-up |
Italy | Tramarin A et al. | 2004 | Pharmacoeconomics | 74 | No information | Prevalence | No information | Bottom-up |
Italy | Merito M et al. | 2005 | Health Policy | 5.422 | No information | Prevalence | No information | Bottom-up |
Italy | Hubben GAA et al. | 2008 | AIDS Care | 119 | Prevalence | Prevalence | Bottom-up | Bottom-up |
United Kingdom | Beck EJ et al. | 1998 | Pharmacoeconomics | 5.783 | No information | Prevalence | Specific hospital activity related to specific hospital unit costs | Bottom-up |
United Kingdom | NPMS Steering Group. | 1998 | International Journal Of STD & AIDS | 6.002 | Prevalence | Prevalence | No information | Bottom-up |
United Kingdom | Beck EJ, Tolley K. | 1998 | International Journal Of STD & AIDS | 5.708 | Prevalence | Prevalence | No information | Bottom-up |
United Kingdom | Sculpher MJ et al. | 1998 | Oficial Journal Of The International AIDS Society | No information | No information | Incidence | No information | Bottom-up |
United Kingdom | Mullins CD et al. | 2000 | Clinical Therapeutics | 4.817 | No information | Prevalence | No information | Bottom-up |
United Kingdom | Evans HER et al. | 2009 | Sexually Transmitted Infections | 2.189 | No information | Prevalence | No information | Bottom-up |